耐多药和广泛耐药结核病中利奈唑胺疗效与安全性评估：印度视角 - Suppr

Suppr

超能文献

Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective.

作者信息

Udwadia Z F, Sen T, Moharil G

出版信息

Eur Respir J. 2010 Apr;35(4):936-8; author reply 938-40. doi: 10.1183/09031936.00132009.

DOI:10.1183/09031936.00132009

PMID:20356997

Abstract

摘要

相似文献

Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective.耐多药和广泛耐药结核病中利奈唑胺疗效与安全性评估：印度视角

Eur Respir J. 2010 Apr;35(4):936-8; author reply 938-40. doi: 10.1183/09031936.00132009.

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India.利奈唑胺：一种有效的、安全的、廉价的药物，用于治疗印度耐多药结核病治疗失败的患者。

Eur Respir J. 2012 Apr;39(4):956-62. doi: 10.1183/09031936.00076811. Epub 2011 Sep 29.

Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis.一名患有广泛耐药结核病的幼儿的长期利奈唑胺治疗

Pediatr Infect Dis J. 2009 Aug;28(8):748-50. doi: 10.1097/INF.0b013e31819bc491.

Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine.阿根廷采用利奈唑胺、莫西沙星和硫利达嗪联合治疗广泛耐药结核病取得成功。

J Antimicrob Chemother. 2012 Feb;67(2):473-7. doi: 10.1093/jac/dkr500. Epub 2011 Dec 1.

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.每日半剂量利奈唑胺治疗难治性耐多药结核病患者的疗效及耐受性

J Antimicrob Chemother. 2006 Sep;58(3):701-4. doi: 10.1093/jac/dkl298. Epub 2006 Jul 19.

Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.每日 300 毫克利奈唑胺治疗耐多药和广泛耐药结核病：51 例患者的更新分析。

J Antimicrob Chemother. 2012 Jun;67(6):1503-7. doi: 10.1093/jac/dks078. Epub 2012 Mar 8.

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.每日300毫克利奈唑胺剂量用于治疗难治性耐多药和广泛耐药结核病。

J Antimicrob Chemother. 2009 Aug;64(2):388-91. doi: 10.1093/jac/dkp171. Epub 2009 May 25.

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.一项关于利奈唑胺治疗耐多药结核病安全性、耐受性及疗效的回顾性TBNET评估。

Eur Respir J. 2009 Aug;34(2):387-93. doi: 10.1183/09031936.00009509. Epub 2009 Mar 12.

[The analysis of clinical data about the treatment of linezolid against tuberculosis].[利奈唑胺治疗结核病的临床数据分析]

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Aug;36(8):601-3.

Lessons from a randomised clinical trial for multidrug-resistant tuberculosis.耐药结核病随机临床试验的经验教训。

Int J Tuberc Lung Dis. 2012 Dec;16(12):1582-7. doi: 10.5588/ijtld.12.0315.

引用本文的文献

Clinical effectiveness and reliability of linezolid in the treatment of pulmonary tuberculosis complicated with severe pneumonia: a meta-analysis.利奈唑胺治疗肺结核合并重症肺炎的临床疗效及可靠性：一项荟萃分析

Am J Transl Res. 2022 Nov 15;14(11):7622-7631. eCollection 2022.

Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India.印度孟买一家三级护理医院耐多药结核病患者中与利奈唑胺耐药相关的临床特征。

J Clin Tuberc Other Mycobact Dis. 2020 Jul 24;20:100175. doi: 10.1016/j.jctube.2020.100175. eCollection 2020 Aug.

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France.利奈唑胺相关神经系统不良事件在耐多药结核病患者中的发生，法国。

Emerg Infect Dis. 2020 Aug;26(8):1792-1800. doi: 10.3201/eid2608.191499.

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.药物相关不良事件在耐多药结核病治疗中的作用：一项个体患者数据荟萃分析。

Lancet Respir Med. 2020 Apr;8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3. Epub 2020 Mar 17.

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis.利奈唑胺在结核分枝杆菌感染的小鼠模型中的药效学相关性及其毒性。

J Infect Dis. 2021 Jun 4;223(11):1855-1864. doi: 10.1093/infdis/jiaa016.

Linezolid for drug-resistant pulmonary tuberculosis.利奈唑胺用于耐药性肺结核

Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD012836. doi: 10.1002/14651858.CD012836.pub2.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.肺耐多药结核病成功治疗结果的相关因素：一项个体患者数据荟萃分析。

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.

Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India.印度孟买耐药结核病患者中与利奈唑胺相关的视神经病变

PLoS One. 2016 Sep 9;11(9):e0162138. doi: 10.1371/journal.pone.0162138. eCollection 2016.

Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.利奈唑胺治疗耐多药（MDR）和广泛耐药（XDR）结核病的疗效与安全性：一项系统评价和荟萃分析

Ann Clin Microbiol Antimicrob. 2016 Jun 22;15(1):41. doi: 10.1186/s12941-016-0156-y.

Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.半胱氨酸154精氨酸取代在核糖体蛋白L3中对结核分枝杆菌恶唑烷酮耐药性的作用。

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3202-6. doi: 10.1128/AAC.00152-16. Print 2016 May.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验